Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Updating risk prediction tools: a case study in prostate cancer.

Ankerst DP, Koniarski T, Liang Y, Leach RJ, Feng Z, Sanda MG, Partin AW, Chan DW, Kagan J, Sokoll L, Wei JT, Thompson IM.

Biom J. 2012 Jan;54(1):127-42. doi: 10.1002/bimj.201100062. Epub 2011 Nov 17.

2.

An updated catalog of prostate cancer predictive tools.

Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW.

Cancer. 2008 Dec 1;113(11):3075-99. doi: 10.1002/cncr.23908. Review.

3.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
4.

Risk calculators and updated tools to select and plan a repeat biopsy for prostate cancer detection.

Sorokin I, Mian BM.

Asian J Androl. 2015 Nov-Dec;17(6):864-9. doi: 10.4103/1008-682X.156859. Review.

5.

Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature.

Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E, Shariat SF.

Eur Urol. 2015 Aug;68(2):238-53. doi: 10.1016/j.eururo.2015.01.032. Epub 2015 Feb 21. Review.

PMID:
25709027
7.

The role of genetic markers in the management of prostate cancer.

Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL, Visakorpi T.

Eur Urol. 2012 Oct;62(4):577-87. doi: 10.1016/j.eururo.2012.05.054. Epub 2012 Jun 5. Review.

PMID:
22695242
8.

Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.

Louie KS, Seigneurin A, Cathcart P, Sasieni P.

Ann Oncol. 2015 May;26(5):848-64. doi: 10.1093/annonc/mdu525. Epub 2014 Nov 17. Review.

PMID:
25403590
9.

Early detection of prostate cancer: European Association of Urology recommendation.

Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, Wirth M, Mottet N; European Association of Urology.

Eur Urol. 2013 Sep;64(3):347-54. doi: 10.1016/j.eururo.2013.06.051. Epub 2013 Jul 9. Review.

PMID:
23856038
10.

Screening and early diagnosis of prostate cancer: an update.

Lumen N, Fonteyne V, De Meerleer G, De Visschere P, Ost P, Oosterlinck W, Villeirs G.

Acta Clin Belg. 2012 Jul-Aug;67(4):270-5. Review.

PMID:
23019802
11.

Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis.

Troyer DA, Mubiru J, Leach RJ, Naylor SL.

Dis Markers. 2004;20(2):117-28. Review.

12.

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.

Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003. Epub 2011 Aug 25. Review.

PMID:
21871709
13.

American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.

Carter HB.

BJU Int. 2013 Sep;112(5):543-7. doi: 10.1111/bju.12318. Review.

14.

[[-2] proPSA: A Novel Marker of Prostate Cancer].

Ishikura K.

Rinsho Byori. 2015 Jan;63(1):84-93. Review. Japanese.

PMID:
26524883
15.

Commercialized biomarkers: new horizons in prostate cancer diagnostics.

Murphy L, Prencipe M, Gallagher WM, Watson RW.

Expert Rev Mol Diagn. 2015 Apr;15(4):491-503. doi: 10.1586/14737159.2015.1011622. Epub 2015 Feb 24. Review.

PMID:
25711191
16.

Prostate cancer biomarkers: an update.

Romero Otero J, Garcia Gomez B, Campos Juanatey F, Touijer KA.

Urol Oncol. 2014 Apr;32(3):252-60. doi: 10.1016/j.urolonc.2013.09.017. Epub 2014 Feb 1. Review.

PMID:
24495450
17.

Validation of biomarker-based risk prediction models.

Taylor JM, Ankerst DP, Andridge RR.

Clin Cancer Res. 2008 Oct 1;14(19):5977-83. doi: 10.1158/1078-0432.CCR-07-4534. Review.

Supplemental Content

Support Center